This course has expired. You can still review the content but course credit is no longer available.
Innovate – Retina, The Stanford Innovation Summit series will take place virtually over the course of three virtual meetings. The summit focuses exclusively on game-changing innovations in medical and surgical retina, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology and the latest advances in retinal pharmacotherapy. This webinar is captured from the third virtual meeting.
Supported by educational grants from Alcon Vision, Apellis, Carl Zeiss Meditec, Genentech, a member of the Roche Group. REGENXBIO and Regeneron Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Jointly Provided by Evolve Medical Education and iVista Medical Education.
ACCREDITATION AND DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and iVista Medical Education. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education LLC designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
David Boyer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Apellis, Bio Time, Boehringer Ingelheim, and Iveric Bio. Grant/Research Support: Apellis, Bio Time, Boehringer Ingelheim, Gemeni, Gyroscope, Iveric Bio, and Roche.
Andrew Chang, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Apellis, Bayer, Novartis, Outlook Therapeutics and Roche. Grant/Research: Bayer, and Novartis. Speaker’s Bureau: Alcon, Bayer, Nidek, Novartis, and Roche.
Diana Do, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Boehringer Ingelheim, Kodiak Sciences, Mallinckrodt, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Boehringer Ingelheim, Novartis and Regeneron Pharmaceuticals. Stock/Shareholder: Kodiak Sciences.
Ninel Z. Gregori, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bionic Vision Technologies. Grant/Research Support: AGTC and Biogen.
Jean-Pierre Hubschmann, MD, has no financial relationships with commercial interests.
Peter Kaiser, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allegro, Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX, Aviceda, Bayer, Bausch and Lomb, Biogen Idec, Bionic Vision Technologies, Boerenger Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, DelSiTech, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Gemini Therapeutics, Glaukos, Innovent, iRenix, IvericBio, jCyte, Kanaph Therapeutics, Kanghong, Kodiak, LensGen, NGM Biopharmaceuticals, Inc., Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra Therapeutics Inc., Omeros, Opthea, Oxurion, Palatin, Regeneron, RegenxBio, Retinal Sciences, Retrope, Roivant, Samsung Bioepis, Sandoz, Santen, Stealth Biotherapeutics, Sustained Nano Systems, Takeda, Théa, 2020 Onsite.
Prithvi Mruthyunjaya, MD, MHS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Castle Biosciences.
Raja Narayanan, MD, has no financial relationships with commercial interests.
Quong Dong Nguyen, MD, MSc, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Asciepix, Regeneron Pharmaceuticals, Rezolute, and Santen. Grant/Research Support: Genentech, Gilead, Novartis, Regeneron Pharmaceuticals and Santen.
Ashish Sharma, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s List: Allergan, Bayer, Intas, Lupin, and Novartis.
Michael Singer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Eyepoint, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alimera, Allergan, Genentech, Novartis, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Eyepoint, Genentech, Novartis, and Regeneron Pharmaceuticals. Stock/Shareholder: Aviceda, Inflammasome, and Nanoscope.
Stephen Smith, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Oncopeptides. Stock/Shareholder: iRenix Medical.
Sunil Srivastava, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, Gilead, Pisvida, Regeneron Pharmacdeuticals, and Santen. Grant/Research Support: Bausch + Lomb, Pisvida, and Santen.
George Williams, MD, has no financial relationships with commercial interests.
Lihteh Wu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau: Bayer, Quantel Medical, and Roche.
Lejla Vajzovic, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, DORC, Genentech, Guidepoint, Gyroscope/Orbit Biomedical, Johnson & Johnson Vision, Novartis, Ocular Surgical, Regenxbio, and Second Sight. Grant/Research Support: Aerie, AGTC, Alcon Laboratories, Aldeyra, Genentech, Gyroscope/Orbit Biomedical, Heidelberg Engineering, National Eye Institute, Novartis, Regenxbio, and Second Sight.
EDITORIAL
The Evolve staff and planners have no financial relationships with commercial interests. iVista staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, iVista, Alcon Vision, Apellis, Carl Zeiss Meditec, Genentech, a member of the Roche Group. REGENXBIO and Regeneron Pharmaceuticals.
